Neoadjuvant therapy

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Annals of Surgical Oncology; October 2014, Volume 21, Issue Read More

2024-02-20T10:41:05-05:00August 7th, 2014|Evidence, NBRST, Neoadjuvant|

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

PUBLICATION:ย  Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS:ย  Read More

2024-03-25T10:46:58-04:00June 12th, 2013|BluePrint, Evidence, Neoadjuvant|

Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

PUBLICATION: Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub Read More

2024-03-25T10:51:13-04:00November 1st, 2012|Evidence, Lobular, MammaPrint, Neoadjuvant, Other|

A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response

PUBLICATION: Breast Cancer Res Treat (2012) 133: 37. https://doi.org/10.1007/s10549-011-1683-z. AUTHORS: Read More

2024-03-25T10:54:08-04:00May 1st, 2012|BluePrint, Evidence, Neoadjuvant|

The 70-gene Signature as a Response Predictor for Neoadjuvant Chemotherapy in Breast Cancer

PUBLICATION: Breast Cancer Res Treat. 2010 Feb;119(3):551-8. doi: 10.1007/s10549-009-0333-1. Epub Read More

2024-03-25T11:03:35-04:00February 1st, 2010|Evidence, MammaPrint, Neoadjuvant|
Go to Top